RESUMEN

In a randomized double-blind study the effect of CaNa2EDTA, a phospholipase A2 inhibitor, was tested as a treatment for acute pancreatitis. CaNa2EDTA was infused intravenously during the first 2 days after admission to hospital, in addition to normal conservative treatment. CaNa2EDTA decreased the serum phospholipase A2 activity and appeared to promote recovery from the illness. To what extent the inhibition of serum phospholipase activity may prevent the progress of severe haemorrhagic pancreatitis or diminish mortality and morbidity in acute pancreatitis should be investigated in further studies.

Asunto(s)

Proteínas de Unión al Calcio , Ácido Edético/uso terapéutico , Glicoproteínas/uso terapéutico , Pancreatitis/tratamiento farmacológico , Fosfolipasas A/antagonistas & inhibidores , Fosfolipasas/antagonistas & inhibidores , Enfermedad Aguda , Anexinas , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pancreatitis/metabolismo , Fosfolipasas A2 , Distribución Aleatoria